Amount of astigmatism and pupil size affect UCVA

Article

Pupil size and the amount of astigmatism affect uncorrected visual acuity (UCVA) in astigmatic eyes, according to an investigation published by the British Journal of Ophthalmology.

Pupil size and the amount of astigmatism affect uncorrected visual acuity (UCVA) in astigmatic eyes, according to an investigation published by the British Journal of Ophthalmology.

Dr Kazutaka Kamiya et al., Department of Ophthalmology, University of Kitasato School of Medicine, Kanagawa, Japan, studied 20 healthy eyes of 20 volunteers. With-the-rule and against-the-rule astigmatism were created after cycloplegic refraction was fully treated. UCVA was measured using artificial pupils of 1 to 5 mm in each eye. To perform a statistical analysis the clinicians used the mean value of three measurements.

Eyes with with-the-rule astigmatism of 1, 2 and 3 D, logMAR UCVA was 0.04±0.08, 0.09±0.09 and 0.16±0.16 for pupils of 1 mm, −0.01±0.09, 0.12±0.15 and 0.33±0.24 for 2 mm pupils, 0.02±0.09, 0.20±0.19 and 0.46±0.30 for 3 mm pupils, 0.02±0.08, 0.24±0.20 and 0.48±0.21 for 4 mm pupils, and 0.08±0.10, 0.33±0.18 and 0.53±0.22 for 5 mm pupils, respectively. Eyes with against-the-rule astigmatism achieved similar results.

The findings advise that, as well as the amount of astigmatism, pupil size should also be considered when improving visual performance in astigmatic eyes.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.